29.04.2014 Views

Xenotransplantation - Nuffield Council on Bioethics

Xenotransplantation - Nuffield Council on Bioethics

Xenotransplantation - Nuffield Council on Bioethics

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Animal-to-Human Transplants : the ethics of xenotransplantati<strong>on</strong><br />

Table 1.1<br />

One year and five year survival rates of<br />

transplant recipients 1<br />

Organ<br />

Survival Rates<br />

1 year 5 years<br />

Kidney 84% 70%<br />

Liver 62% 54%<br />

Heart 73% 62%<br />

1.4 Organ transplantati<strong>on</strong> offers several benefits. For some c<strong>on</strong>diti<strong>on</strong>s, such as advanced<br />

heart failure, treatment with drugs or restorative surgery may not be possible and a<br />

transplant will provide the <strong>on</strong>ly way of replacing a failed vital organ. Heart or liver<br />

transplantati<strong>on</strong> can offer many additi<strong>on</strong>al years of life for people who otherwise<br />

might not survive, as the <strong>on</strong>e year and five year survival rates for liver and heart<br />

transplant recipients show (Table 1.1). Worldwide there are patients whose lives have<br />

been c<strong>on</strong>siderably extended following transplantati<strong>on</strong>: by 23 years after liver<br />

transplants and 20 years after heart transplants.<br />

1.5 Transplantati<strong>on</strong> can not <strong>on</strong>ly increase the length of life, but also improve its quality.<br />

Even where there is an alternative form of treatment, such as dialysis for end-stage<br />

kidney failure, a transplant frequently offers a higher quality of life despite the<br />

drawbacks of the c<strong>on</strong>tinuous immunosuppressive regime most transplant recipients<br />

require. Kidney transplant recipients are freed from the necessity of regular,<br />

uncomfortable and time-c<strong>on</strong>suming treatment and are restored to a level of health not<br />

possible with dialysis. They are able to eat and drink freely, and to travel, in ways<br />

that people <strong>on</strong> l<strong>on</strong>g-term dialysis often cannot. Patient support groups describe heart<br />

transplant recipients who are able to climb hills, and undertake other activities, that<br />

they would not have been able to manage before the operati<strong>on</strong>. Some transplant<br />

recipients participate in highly demanding sporting c<strong>on</strong>tests such as the Transplant<br />

Games.<br />

1.6 It should be noted that, c<strong>on</strong>trary to some mispercepti<strong>on</strong>, transplantati<strong>on</strong> is not<br />

particularly expensive. Estimates are very difficult to make, but it is possible to get<br />

a rough idea of the relative costs of different treatments. A kidney transplant<br />

operati<strong>on</strong> costs in the regi<strong>on</strong> of £10,000. After that, the cost of immunosuppressive<br />

drugs and other follow-up treatment is about £3,000 a year. In c<strong>on</strong>trast, dialysis costs<br />

about £18,000 a year if the patient is treated in hospital, and about £11,000 if the<br />

patient is treated at home. Thus, kidney transplantati<strong>on</strong> is a more cost-effective<br />

1<br />

Source: United Kingdom Transplant Support Service Authority (UKTSSA) publicati<strong>on</strong>s: Renal Transplant<br />

Audit 1984-1993; Liver Transplant Audit 1985-1992; Thoracic Organ Transplant Audit 1985-1992.<br />

2

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!